home / stock / bivi / bivi news

BIVI News and Press, BioVie Inc. From 03/15/23

Stock Information
Company Name: BioVie Inc.
Stock Symbol: BIVI
Market: NASDAQ
Website: biovieinc.com
Menu
BIVI BIVI Quote BIVI Short BIVI News BIVI Articles BIVI Message Board
Get BIVI Alerts

News, Short Squeeze, Breakout and More Instantly...
BIVI - BioVie Day says webinar registration now open for investors

--News Direct-- BioVie CEO Cuong Do joins Proactive's Natalie Stoberman to share the details of the company's upcoming BioVie Day webinar on March 23. Do says BioVie Day will feature a comprehensive overview of the company’s programs in Alzheimer’s disease, Parkinson’...
BIVI - BioVie Announces Registration Details for "BioVie Day" Webinar

CARSON CITY, Nev., March 14, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease...

BIVI - BioVie pauses mid-stage trial for ascites candidate after encouraging data

2023-03-13 13:59:32 ET Clinical-stage biotech BioVie ( NASDAQ: BIVI ) announced Monday that the company halted patient enrollment in Phase 2b clinical trial for ascites candidate BIV201 after generating "compelling" data from its first 15 patients. The study is designed to e...

BIVI - BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouraging Efficacy Data is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational Trial

CARSON CITY, Nev., March 13, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease...
BIVI - Why Shares of BioVie Jumped This Week

2023-03-10 11:04:28 ET Shares of clinical-stage biotech company BioVie (NASDAQ: BIVI) were up 19.2% for the week as of Friday morning, according to data provided by S&P Global Market Intelligence . The stock closed last week at $6.87 and rose to a high of $9.40 on Thursd...

BIVI - BioVie to Participate in the Oppenheimer 33rd Annual Healthcare Conference

CARSON CITY, Nev., March 09, 2023 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease...

BIVI - BioVie reports encouraging data from mid-stage Parkinson's Disease trial

2023-03-06 09:17:30 ET BioVie ( NASDAQ: BIVI ) announces additional preliminary findings from its Parkinson’s Disease (PD) Phase 2 trial. The findings show that significantly more patients treated with the Company’s drug, NE3107, were assessed as being in...
BIVI - BioVie Announces Additional Findings from Phase 2 Parkinson's Disease Trial: More patients treated with NE3107 experienced morning "on state" with levodopa withheld overnight compared to those treated with placebo

CARSON CITY, Nev., March 06, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease...

BIVI - Why Shares of BioVie Jumped 51.7% in February

Shares of clinical-stage biotech BioVie (NASDAQ: BIVI) rose 51.7% in February, according to data provided by S&P Global Market Intelligence . The healthcare company closed out January at $5.07, then rose to $7.88 on Feb. 28. It's worth noting that the run continued after the m...

BIVI - BioVie Announces Completion of Patient Enrollment in Phase 3 Trial Assessing NE3107 in Alzheimer's Disease

CARSON CITY, Nev., March 02, 2023 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver di...
Previous 10 Next 10